ArticleApplied biochemistry and biotechnology2025
Alhagi maurorum: A Medicinal Treasure Trove Empowered by Copper Oxide Nanoparticles for Enhanced Secondary Metabolite Synthesis.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanomaterial-induced modulation of morpho-physio-biochemical attributes and enhancement of anticancer compounds in Tagetes erecta L. callus cultures.Scientific reports · 2026Article
- Impact of Copper Oxide Nanoparticles on Adventitious Shoot Regeneration, Axillary Shoot Multiplication, Rooting, and Bioactive Compounds inPlants (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the potential of green-synthesized copper oxide nanoparticles (CuO NPs) to enhance biomass production and therapeutic metabolite yields in Alhagi maurorum, a medicinal plant of significant pharmaceutical value. CuO NPs were biosynthesized using A. maurorum leaf extract as a reducing and capping agent, with characterization confirmed via UV-Vis spectroscopy, FTIR, XRD, SEM, TEM, and zeta potential analysis. Nanoparticles ranged from 7-30 nm in size. Callus induction and proliferation were established using Murashige and Skoog (MS) media supplemented with varying concentrations (0-12 mg/L) of CuO NPs combined with plant growth regulators. Maximum callus fresh weight (9.02 mg in cotyledon and 8.46 mg in hypocotyl) was achieved in MS media containing 3.0 mg/L BAP, 0.1 mg/L NAA, and 0.50 mg/L kinetin without CuO NPs. However, CuO NPs significantly enhanced metabolite production in a dose-dependent manner. Analysis of variance revealed statistically significant differences (p=0.001) across all biochemical parameters tested, with high F-values for peroxidase activity (7,755.74), total flavonoids (5,195.02), and total soluble sugar (5,702.18). At 8 mg/L CuO NPs, callus cultures exhibited elevated levels of total free amino acids (12.49±0.023 mg/g DW) and total soluble protein (35.617±0.033 mg/g DW), while control samples produced higher starch (35.547±0.23 mg/g DW) and total soluble sugar (121.56±0.091 mg/g DW) content. Significantly, CuO NP-treated cultures demonstrated enhanced secondary metabolite synthesis, with maximum total phenolic compounds (156.477±0.167 mg/g DW GAE) and flavonoids (58.307±0.179 mg/g QE) at 8 and 10 mg/L CuO NPs, respectively. Antioxidant enzyme analysis revealed that cotyledon-derived callus exhibited peak activities at specific CuO NP concentrations: superoxide dismutase (84.5±0.254% inhibition) and glutathione reductase (0.75±0.006% inhibition) at 8 mg/L; peroxidase (3.137±0.009 U), catalase (77.35±0.152 U), and ascorbate peroxidase (0.43±0.006 mM/mg FW) at 10 mg/L. HPLC analysis confirmed the novel presence of lupeol, an anticancer compound, in regenerated roots. These findings demonstrate the potential of CuO NPs for enhancing therapeutic metabolite production in A. maurorum tissue culture while suggesting optimal concentration ranges (8-10 mg/L) for maximum benefits. Further research is necessary to elucidate the molecular mechanisms governing nanoparticle-plant interactions and to address potential health implications.
Indexed as
Identifiers
40423744What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.